Key result
Epirubicin chemotherapy caused life-threatening acute heart failure and splenic thromboembolism in a 42-year-old woman, which gradually resolved with supportive care.
Case Report (n=1)
No
Epirubicin can cause severe, life-threatening cardiotoxicity and thromboembolism, but patients can fully recover with appropriate supportive heart failure care.
Answers are grounded in this paper and cite their sources.
Highlights potential for reversible epirubicin cardiotoxicity and thromboembolism; leaves open incidence, predictors, and prevention strategies.
We present the case of a 42-year-old Japanese woman who developed acute heart failure after chemotherapy with epirubicin for breast cancer. Echocardiography revealed a cardiac dysfunction with left ventricular thrombus. Serial serum troponin T tests were positive over a 5-week period, and an endomyocardial biopsy demonstrated ultrastructural lesions which were similar to those caused by cardiotoxicities due to doxorubicin. Although the patient developed splenic thromboembolism, her cardiac function recovered gradually, and she regained full range of her activities. This case report demonstrates that epirubicin-associated cardiotoxicity causes life-threatening heart failure and supportive care is important until the patient recovers from acute intoxication.
No takes yet. Share an insight, caveat, or question.
Okura et al. (2012) conducted a case report in Epirubicin-associated cardiotoxicity (n=1). Epirubicin was evaluated. Epirubicin chemotherapy caused life-threatening acute heart failure and splenic thromboembolism in a 42-year-old woman, which gradually resolved with supportive care.
Synapse has enriched 10 related papers. Consider them for comparative context: